Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.
Gilbert
Jill
J
Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. jill.gilbert@vanderbilt.edu
Argiris
Athanassios
A
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003131:Combined Modality Therapy; D051546:Cyclooxygenase 2; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D015996:Survival Rate; D016896:Treatment Outcome; D048490:raf Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D066246:ErbB Receptors; D048490:raf Kinases